Monitoring Intravitreal Injection Patients - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Monitoring Intravitreal Injection Patients

  • By

  • Pamela E. Theriot, OD

  • March 2, 2026

  • 4 min

Share

Clinical Scorecard: Monitoring Intravitreal Injection Patients

At a Glance

CategoryDetail
ConditionNeurotrophic Keratitis (NK) induced by intravitreal injections
Key MechanismsCorneal nerve damage and reduced nerve density after multiple intravitreal injections, especially anti-VEGF agents which impair corneal nerve regeneration
Target PopulationPatients receiving intravitreal injections for age-related macular degeneration and diabetic macular edema
Care SettingOphthalmology and optometry clinics managing patients undergoing intravitreal injections

Key Highlights

  • Corneal nerve length and density decrease notably after the third intravitreal injection.
  • Anti-VEGF injections can cause more corneal damage due to VEGF's role in nerve regeneration.
  • Early detection of NK via corneal sensitivity testing and fluorescein staining is critical to prevent progression.

Guideline-Based Recommendations

Diagnosis

  • Obtain detailed history of number and type of intravitreal injections.
  • Assess risk factors including diabetes, stroke, autoimmune disease, dry eye disease, and prior ocular surgeries.
  • Use the Ocular Surface Disease Index survey to evaluate vision-related symptoms.
  • Perform corneal sensitivity testing using Cochet-Bonnet or Brill esthesiometers, cotton wisp, or unwaxed dental floss without prior eye drop instillation.
  • Evaluate corneal fluorescein staining patterns focusing on central cornea and punctate epithelial defects.

Management

  • Educate patients on the importance of regular follow-up to monitor for NK progression.
  • Early intervention upon detection to prevent progression to stage 3 NK and vision loss.

Monitoring & Follow-up

  • Regular screening of intravitreal injection patients for signs of NK using sensitivity testing and slit lamp examination.
  • Monitor for conjunctival hyperemia, epithelial irregularity, stromal haze, punctate keratopathy, superficial vascularization, and stromal scarring.

Risks

  • Progression to severe NK (stage 3) characterized by central corneal ulcers, stromal thinning, and melting requiring urgent care.
  • Potential vision loss if NK is not detected and managed early.

Patient & Prescribing Data

Patients receiving multiple intravitreal injections, particularly anti-VEGF treatments.

Corneal nerve damage risk increases after the third injection; anti-VEGF agents pose higher risk due to interference with nerve healing.

Clinical Best Practices

  • Do not instill eye drops before corneal sensitivity testing to avoid false results.
  • Use quantitative corneal sensitivity grading scales for consistent monitoring.
  • Inform patients about NK risks and signs to encourage adherence to follow-up appointments.
  • Screen regularly to identify early NK and intervene promptly to prevent progression.

Related Resources & Content

Original Source(s)

Related Content